Navigation Links
Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
Date:11/8/2007

velop, manufacture, license and sell its

products or product candidates;

* the Company's ability to enter into and successfully execute license

and collaborative agreements, if any;

* the adequacy of the Company's capital resources and cash flow

projections, and the Company's ability to obtain sufficient financing

to maintain the Company's planned operations;

* the adequacy of the Company's patents and proprietary rights;

* the impact of litigation that has been brought against the Company and

its officers and directors and any proposed settlement of such

litigation;

* the Company's ability to retain compliance with the NASDAQ's listing

qualifications; and

* the other risks described under Certain Risks and Uncertainties Related

to the Company's Business, as contained in the Company's Annual Report

on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2006 and its most recent quarterly report on Form 10-Q.

CONTACT:

Brian Korb

The Trout Group

908-286-3980

info@genta.com


'/>"/>
SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
2. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
3. New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
4. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
5. DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
6. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
7. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
10. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
11. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... WABC Radio show out of New York City, ... will be hosting California-based Vet-Stem, Inc.’s Founder and CEO, Robert ... pets. Dr. Harman first visited the show in November ... pets suffering from osteoarthritis and other degenerative diseases, as well ... , Young has invited Dr. Harman back to dial down ...
(Date:7/25/2014)... 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... development and commercialization of a once-daily, oral therapy for ... announced financial results for the period ended June 30, ... , Reported cash and cash equivalents totaling $37.4 million ... 31, 2013.  , Reported a net loss of ...
(Date:7/25/2014)... -- Sinovac Biotech Ltd. (Nasdaq: SVA ), a ... , today announced that it will release its unaudited financial ... market close on Thursday, August 14, 2014 EDT. The Company ... on Friday, August 15, 2014, at 8:00 a.m. EDT (Friday, ... review the Company,s financial results and provide an update on ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Gain ... Global Supply Chain of the biotech industry. Nominations ... Innovation Awards, brought to you by the ... organization of supply chain management professionals for the ... to stakeholders of the Biotech industry – Manufacturers, ...
Breaking Biology Technology:Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3
... ... in plants , ... Netherlands (PRWEB) June 28, 2010 -- Genedata, a leading provider of advanced software solutions for ... Metabolomics Conference 2010. Part of Genedata Expressionist 6 for omics data management, the ...
... ... cognition grew 31% in 2009, to $295M worldwide; and is forecasted to reach $4B in ... San Francisco, CA ... technologies to assess, enhance and treat cognition, or digital brain health and fitness ...
... BEIJING , June 27, 2010 , ... - Outstanding Young Women Biologists, Chemists, Physicists and,Mathematicians Recognized Across the Developing World ... The Elsevier Foundation, TWAS and TWOWS ... Middle East , Asia , Latin America and the Caribbean for ...
Cached Biology Technology:Genedata's Refiner MS Used by Max Planck Institute will Demo at Metabolomics Conference 2010 2Genedata's Refiner MS Used by Max Planck Institute will Demo at Metabolomics Conference 2010 3Genedata's Refiner MS Used by Max Planck Institute will Demo at Metabolomics Conference 2010 4New Report Finds A Brain Health Revolution in the Making, Driven by Digital Technology and Neuroplasticity Research 2New Report Finds A Brain Health Revolution in the Making, Driven by Digital Technology and Neuroplasticity Research 3New Report Finds A Brain Health Revolution in the Making, Driven by Digital Technology and Neuroplasticity Research 4New Report Finds A Brain Health Revolution in the Making, Driven by Digital Technology and Neuroplasticity Research 5Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 2Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 3Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 4Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 5Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 6Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 7
(Date:7/27/2014)... studies to date, researchers from the U.K. provide national, ... C virus (HCV). Findings published in Hepatology, a journal ... Diseases, indicate that genotype 1 is the most prevalent ... one-third reside in East Asia. Genotype 3, at just ... followed by genotypes 2, 4, 6, and 5. ...
(Date:7/27/2014)... like bacteria and fungi can evade treatment by acquiring ... drugs. These permanent mutations were once thought to be ... a new study has shown that microorganisms can use ... epimutations -- to gain the benefits of drug resistance ... discovered in a fungus called Mucor circinelloides, it is ...
(Date:7/27/2014)... scientists at Barts Cancer Institute have found that targeting ... significantly more effective, according to research published in ... Institute, part of Queen Mary University of London, have ... signals the body to repair itself after chemotherapy or ... the researchers removed FAK from blood vessels that grew ...
Breaking Biology News(10 mins):Hepatitis C virus genotype 1 is most prevalent worldwide 2Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3New drug target can break down cancer's barrier against treatment 2
... A new study has shown that racehorses are extremely ... can adapt very quickly to sudden shifts in the 24-hour ... with unexpected benefits on their physical performance. The ... of Medical and Veterinary Sciences is published in the ...
... This release is available in German . ... annelid Platynereis swim freely in the open water. ... hair-like structures forming a band along the larval body and ... and downward to their appropriate water depth. Scientists of the ...
... EAST LANSING, Mich. By analyzing which animal models ... Michigan State University researcher is hoping to overcome one ... disease: The genetic complexity of the tumors themselves. ... of Physiology, has received a $450,000 grant from the ...
Cached Biology News:Light dependency underlies beneficial jetlag in racehorses 2Light dependency underlies beneficial jetlag in racehorses 3Simple nerve cells regulate swimming depth of marine plankton 2Simple nerve cells regulate swimming depth of marine plankton 3Cracking breast cancer's genetic code may lead to new treatments 2